Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 14/20 | 1.00 |
| ▸ | C1R | P00736 | 2/20 | 0.59 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8214558 | 0.92 | ELANE (0.86) | ELANEC1RPBRM1 | |
| SCHEMBL8205929 | 0.90 | ELANE (0.82) | ELANEC1RPBRM1 | |
| SCHEMBL8210841 | 0.88 | ELANE (0.78) | ELANEC1R | |
| SCHEMBL913593 | 0.87 | ELANE (0.77) | ELANEC1R | |
| SCHEMBL12897182 | 0.87 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL8216128 | 0.85 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL8213453 | 0.84 | ELANE (0.72) | ELANEC1R | |
| SCHEMBL12897219 | 0.83 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL8205926 | 0.82 | ELANE (0.82) | ELANEC1R | |
| SCHEMBL9984780 | 0.79 | ELANE (1.00) | ELANEC1RPBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7879846-B2 | e.g. 2-(2-Imidazol-1-yl-pyridin-3-yl)-5-methyl-4H-benz[d][1,3]oxazin-4-one ; neutrophil elastase inhibitor; antiinflammatory agent, respiratory system disorders | Kyorin Pharmaceutical Co.., Ltd. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161290-A1 | Serine hydrolase inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161290-A1 | Serine hydrolase inhibitors | SERPINB1, ELANE, EPX | ELANE 2/4885C1R 1386/4885PBRM1 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.